Bristol Myers CEO on second quarter, infrastructure

The CEO of Bristol Myers Squibb discusses the potential impact of an infrastructure deal on corporate taxes and the importance of maintaining global competitiveness. The conversation highlights the company's focus on innovation, resilience during the pandemic, and the significance of vaccination and safety measures. Additionally, the CEO elaborates on business development strategies and the competition for talent in the pharmaceutical industry.

What is the main concern for Bristol Myers Squibb regarding the potential infrastructure deal?

• Decreased demand for their products

• Lack of innovation in the industry

• Higher corporate taxes affecting global competitiveness

• Increased competition from local companies

How has Bristol Myers Squibb's portfolio performed during the pandemic?

• It has stopped production completely

• It has been very resilient

• It has seen a decline in new medicines

• It has struggled to maintain sales

What measures has Bristol Myers Squibb implemented to ensure workforce safety during the pandemic?

• Reduction in workforce size

• Use of masks and social distancing

• Increased production hours

• Mandatory remote work for all employees

What is a key component of Bristol Myers Squibb's business development strategy?

• Reducing investment in new medicines

• Combining internal R&D with external innovation

• Acquiring companies in unrelated fields

• Focusing solely on internal R&D

What area did Bristol Myers Squibb strengthen through recent deals?

• Cell therapy

• Protein homeostasis

• Oncology

• Cardiovascular medicines

What is Bristol Myers Squibb's approach to attracting talent?

• Offering the highest salaries in the industry

• Providing extensive remote work options

• Focusing on the strength of their pipeline and quality of science

• Hiring only from top universities

What has been a significant factor in Bristol Myers Squibb's success in attracting talent?

• Their remote work policy

• Their focus on cardiovascular medicines

• The quality of science at the company

• Their international presence